- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01484015
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
Prolonged Infusion Compared to Standard Infusion Cefepime as Empiric Treatment of Febrile Neutropenia: A Pilot Study
Study Overview
Status
Conditions
- Myelodysplastic Syndromes
- Breast Cancer
- Primary Myelofibrosis
- Multiple Myeloma
- Ovarian Epithelial Cancer
- Chronic Myelomonocytic Leukemia
- Neutropenia
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Nodal Marginal Zone B-cell Lymphoma
- Splenic Marginal Zone Lymphoma
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma
- Chronic Lymphocytic Leukemia
- Chronic Myelogenous Leukemia
- Prolymphocytic Leukemia
- Ovarian Germ Cell Tumor
- Chronic Neutrophilic Leukemia
- Small Lymphocytic Lymphoma
- Plasma Cell Neoplasm
- Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
- Myelodysplastic/Myeloproliferative Neoplasms
- Adult Acute Myeloid Leukemia
- Disseminated Neuroblastoma
- Adult Lymphoblastic Lymphoma
- Adult Acute Lymphoblastic Leukemia
- Mycosis Fungoides/Sezary Syndrome
- Grade 1 Follicular Lymphoma
- Grade 2 Follicular Lymphoma
- Chronic Eosinophilic Leukemia
- Adult Hodgkin Lymphoma
- Adult Diffuse Large Cell Lymphoma
- Poor Prognosis Metastatic Gestational Trophoblastic Tumor
- Grade 3 Follicular Lymphoma
- Adult Burkitt Lymphoma
- Adult Diffuse Mixed Cell Lymphoma
- Adult Diffuse Small Cleaved Cell Lymphoma
- Adult Immunoblastic Large Cell Lymphoma
- Cutaneous T-cell Non-Hodgkin Lymphoma
- Malignant Testicular Germ Cell Tumor
Intervention / Treatment
Detailed Description
OBJECTIVES:
I. The objective of this study is to describe outcomes associated with prolonged infusion (3 hours) compared to standard infusion (30 minutes) cefepime (cefepime hydrochloride) among patients being treated empirically for febrile neutropenia.
OUTLINE: Patients are randomized 1 of 2 treatment arms.
All patients receive cefepime hydrochloride intravenously (IV) over 30 minutes as their first dose.
ARM I: Patients receive cefepime hydrochloride intravenously (IV) over 30 minutes.
ARM II: Patients receive cefepime hydrochloride IV over 3 hours. Treatment repeats every 8 hours.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest University Health Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Absolute neutrophil count < 500 cells/mm^3 or < 1000 cells/mm^3 with a predicted decrease to < 500 cells/mm^3
- Temperature > 38.0 degrees Celsius
- Received chemotherapy or stem-cell transplant as treatment for malignancy or myelodysplastic syndrome (MDS)
- Cefepime prescribed at a dose of 2 grams IV every 8 hours
Exclusion Criteria:
- Allergy to a cephalosporin antibiotic
- Estimated creatinine clearance < 50 milliliters/minute
- Concurrent anti-gram negative antimicrobials
- Diagnostic criteria suggestive of sepsis
- Circumstances which may make 3 hour infusion impractical
- Solid tumor malignancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Arm I (standard infusion)
Patients receive cefepime hydrochloride IV over 30 minutes.
|
Given IV
Other Names:
|
EXPERIMENTAL: Arm II (prolonged infusion)
Patients receive cefepime hydrochloride IV over 3 hours.
Treatment repeats every 8 hours.
|
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Defervescence (without hypothermia)
Time Frame: 72 hours
|
Comparison between groups will be done using the chi square test.
T-tests will be used for continues variables.
Survival data will be estimated using the Kaplan-Meier method, with the formal test of group comparisons done using Cox's Proportional Hazards Model.
|
72 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Clinical success or failure
Time Frame: approximately 24 days
|
approximately 24 days
|
Need for additional antimicrobials
Time Frame: approximately 24 days
|
approximately 24 days
|
Mortality (in-house)
Time Frame: approximately 24 days
|
approximately 24 days
|
Time to defervescence
Time Frame: approximately 24 days
|
approximately 24 days
|
Hospital length of stay
Time Frame: approximately 24 days
|
approximately 24 days
|
Successful treatment of baseline infection
Time Frame: approximately 24 days
|
approximately 24 days
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: John Williamson, Wake Forest University Health Sciences
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Virus Diseases
- Infections
- Immune System Diseases
- Neoplasms by Histologic Type
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Disease
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Bone Marrow Diseases
- Hematologic Diseases
- Endocrine Gland Neoplasms
- Genital Neoplasms, Male
- Testicular Diseases
- Hemorrhagic Disorders
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Nerve Tissue
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- DNA Virus Infections
- Bacterial Infections and Mycoses
- Tumor Virus Infections
- Pregnancy Complications
- Agranulocytosis
- Leukopenia
- Leukocyte Disorders
- Leukemia, Lymphoid
- Epstein-Barr Virus Infections
- Herpesviridae Infections
- Leukemia, B-Cell
- Neuroectodermal Tumors, Primitive
- Eosinophilia
- Ovarian Neoplasms
- Pregnancy Complications, Neoplastic
- Neuroectodermal Tumors, Primitive, Peripheral
- Neoplasms
- Lymphoma
- Lymphoma, Follicular
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Syndrome
- Myelodysplastic Syndromes
- Neoplasms, Germ Cell and Embryonal
- Testicular Neoplasms
- Primary Myelofibrosis
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Leukemia
- Leukemia, Myeloid
- Hodgkin Disease
- Lymphoma, Non-Hodgkin
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myelomonocytic, Juvenile
- Mycoses
- Neutropenia
- Burkitt Lymphoma
- Lymphoma, Mantle-Cell
- Lymphoma, B-Cell, Marginal Zone
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Lymphoma, Large-Cell, Immunoblastic
- Plasmablastic Lymphoma
- Leukemia, Lymphocytic, Chronic, B-Cell
- Carcinoma, Ovarian Epithelial
- Hypereosinophilic Syndrome
- Lymphoma, T-Cell
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Trophoblastic Neoplasms
- Neuroblastoma
- Lymphoma, T-Cell, Cutaneous
- Plasmacytoma
- Mycosis Fungoides
- Sezary Syndrome
- Myeloproliferative Disorders
- Myelodysplastic-Myeloproliferative Diseases
- Leukemia, Prolymphocytic
- Febrile Neutropenia
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
- Leukemia, Neutrophilic, Chronic
- Anti-Infective Agents
- Anti-Bacterial Agents
- Cefepime
Other Study ID Numbers
- IRB00015247
- NCI-2011-02422 (REGISTRY: CTRP (Clinical Trial Reporting Program))
- CCCWFU 02110 (OTHER: Wake Forest University Health Sciences)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelodysplastic Syndromes
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic SyndromesUnited States
-
National Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic SyndromesUnited States
-
GCP-Service International West GmbHSaint-Louis Hospital, Paris, France; University of Florence; Medical University... and other collaboratorsNot yet recruitingLow Risk Myelodysplastic SyndromesSpain, Poland, Italy, Germany, France
-
Dana-Farber Cancer InstituteCompletedMyelodysplastic Syndromes (MDS)United States
-
TJ Biopharma Co., Ltd.Recruiting
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI)RecruitingMyelodysplastic Syndromes (MDS)United States, Israel
-
AbbVieCelgene; Genentech, Inc.CompletedMyelodysplastic Syndromes (MDS)United States, Australia, Germany
-
AbbVieGenentech, Inc.Active, not recruitingMyelodysplastic Syndromes (MDS)United States, Australia, Canada, France, Germany, Italy, United Kingdom
-
The First Affiliated Hospital with Nanjing Medical...UnknownMyelodysplastic Syndromes (MDS)China
-
Sumitomo Pharma America, Inc.TerminatedMyelodysplastic Syndromes (MDS)United States
Clinical Trials on cefepime hydrochloride
-
Hospital de Clinicas de Porto AlegreUnknownUrinary Tract Infection | Respiratory Tract InfectionBrazil
-
AllecraMedpace, Inc.CompletedUrinary Tract InfectionsHungary, Czechia, Poland, Slovakia, Ukraine
-
WockhardtMedpace, Inc.RecruitingAcute Pyelonephritis | Complicated Urinary Tract InfectionUnited States, China, India, Lithuania, Mexico, Peru, Poland, Bulgaria, Estonia
-
Venatorx Pharmaceuticals, Inc.CompletedHealthy SubjectsUnited States
-
Venatorx Pharmaceuticals, Inc.National Institutes of Health (NIH)CompletedHealthy SubjectsUnited States
-
Venatorx Pharmaceuticals, Inc.Biomedical Advanced Research and Development AuthorityNot yet recruitingHospital-acquired Pneumonia | Ventilator-associated Pneumonia
-
AllecraCompleted
-
Venatorx Pharmaceuticals, Inc.CompletedUrinary Tract Infections | Acute PyelonephritisUnited States, Argentina, Brazil, Bulgaria, China, Croatia, Hungary, Latvia, Mexico, Peru, Romania, Russian Federation, Serbia, Turkey, Ukraine
-
CPL AssociatesElan PharmaceuticalsCompleted
-
Hospital Authority, Hong KongCompleted